Physician profile
William King
NPI 1427079250
$226,552.91
in general payments reported to CMS, 2019-2025
31 companies · $109K in 2025
The $109K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,281 · 2020: $5,073 · 2021: $8,963 · 2022: $24K · 2023: $20K · 2024: $57K · 2025: $109K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $124K · Consulting Fee: $27K · Travel and Lodging: $24K · Food and Beverage: $11K · Education: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124,102.50 |
| Consulting Fee | $26,880.00 |
| Travel and Lodging | $24,282.56 |
| Food and Beverage | $11,128.26 |
| Education | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $157,246.95 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Gilead Sciences, INC. | $64,754.52 | 2019-2025 | Yeztugo, Descovy, Biktarvy |
| Glaxosmithkline, LLC. | $733.26 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $500.62 | 2022-2025 | |
| Abbvie INC. | $430.41 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $421.67 | 2019-2025 | Pifeltro, Verquvo, Delstrigo |
| Pfizer INC. | $328.24 | 2019-2025 | |
| Janssen Biotech, INC. | $200.27 | 2019-2020 | |
| Celgene Corporation | $196.15 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $192.99 | 2022-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $192.52 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Emd Serono, INC. | $190.88 | 2023-2024 | Serostim, Serostim |
| Janssen Products, Lp | $169.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.07 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.04 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $115.32 | 2025 | Uzedy |
| Progenics Pharmaceuticals, INC. | $85.20 | 2023 | Pylarify |
| Arbor Pharmaceuticals, INC. | $83.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $51.58 | 2022-2023 | |
| Kaleo, INC. | $46.15 | 2019 | |
| Novo Nordisk INC | $40.11 | 2019 | |
| Amgen INC. | $39.28 | 2025 | Repatha |
| Sanofi-Aventis U.S. LLC | $34.92 | 2019-2022 | |
| Napo Pharmaceuticals INC | $32.80 | 2023 | Mytesi |
| Verona Pharma, INC. | $30.29 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Emergent Biosolutions INC. | $23.19 | 2019 | |
| Pacira Therapeutics, INC. | $21.82 | 2019 | |
| Assertio Therapeutics, INC. | $20.88 | 2020 | |
| Theratechnologies INC. | $20.06 | 2019 | |
| Scilex Pharmaceuticals INC. | $18.58 | 2023 | Ztlido |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.